These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26517812)
1. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822 [TBL] [Abstract][Full Text] [Related]
3. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. Greish K; Jasim A; Parayath N; Abdelghany S; Alkhateeb A; Taurin S; Nehoff H J Drug Target; 2018 Sep; 26(8):692-708. PubMed ID: 29251531 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Johnson FM; Saigal B; Talpaz M; Donato NJ Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Eustace AJ; Crown J; Clynes M; O'Donovan N J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558 [TBL] [Abstract][Full Text] [Related]
6. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Sen B; Peng S; Saigal B; Williams MD; Johnson FM Clin Cancer Res; 2011 Feb; 17(3):514-24. PubMed ID: 21106725 [TBL] [Abstract][Full Text] [Related]
7. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476 [TBL] [Abstract][Full Text] [Related]
8. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment. Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967 [TBL] [Abstract][Full Text] [Related]
9. Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. Sie M; den Dunnen WF; Lourens HJ; Meeuwsen-de Boer TG; Scherpen FJ; Zomerman WW; Kampen KR; Hoving EW; de Bont ES PLoS One; 2015; 10(3):e0122555. PubMed ID: 25799134 [TBL] [Abstract][Full Text] [Related]
10. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251 [TBL] [Abstract][Full Text] [Related]
11. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells. Atif F; Patel NR; Yousuf S; Stein DG PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872 [TBL] [Abstract][Full Text] [Related]
12. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition. Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453 [TBL] [Abstract][Full Text] [Related]
13. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020 [TBL] [Abstract][Full Text] [Related]
14. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998 [TBL] [Abstract][Full Text] [Related]
15. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors. Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505 [TBL] [Abstract][Full Text] [Related]
16. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662 [TBL] [Abstract][Full Text] [Related]
17. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Miekus K; Kijowski J; Sekuła M; Majka M Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268 [TBL] [Abstract][Full Text] [Related]
18. c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. Bunda S; Heir P; Li ASC; Mamatjan Y; Zadeh G; Aldape K Mol Cancer Res; 2020 May; 18(5):774-786. PubMed ID: 32029440 [TBL] [Abstract][Full Text] [Related]
19. Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. Barrette AM; Bouhaddou M; Birtwistle MR ACS Chem Neurosci; 2018 Jan; 9(1):118-129. PubMed ID: 28950062 [TBL] [Abstract][Full Text] [Related]
20. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]